BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 26287143)

  • 1. Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients.
    Ebenhan T; Vorster M; Marjanovic-Painter B; Wagener J; Suthiram J; Modiselle M; Mokaleng B; Zeevaart JR; Sathekge M
    Molecules; 2015 Aug; 20(8):14860-78. PubMed ID: 26287143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convenient Preparation of [(68)Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy.
    Satpati D; Shinto A; Kamaleshwaran KK; Sane S; Banerjee S
    Mol Imaging Biol; 2016 Jun; 18(3):420-7. PubMed ID: 26983703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Quality Control of the ITG 68Ge/68Ga Generator and Synthesis of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for Clinical Imaging.
    Amor-Coarasa A; Schoendorf M; Meckel M; Vallabhajosula S; Babich JW
    J Nucl Med; 2016 Sep; 57(9):1402-5. PubMed ID: 27103024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of Labeling PSMA
    Eppard E; Homann T; de la Fuente A; Essler M; Rösch F
    J Nucl Med; 2017 Mar; 58(3):432-437. PubMed ID: 28082433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
    Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
    J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection Efficacy of Hybrid
    Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
    Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
    Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
    Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Young JD; Abbate V; Imberti C; Meszaros LK; Ma MT; Terry SYA; Hider RC; Mullen GE; Blower PJ
    J Nucl Med; 2017 Aug; 58(8):1270-1277. PubMed ID: 28408532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
    Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C
    Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer.
    Pyka T; Weirich G; Einspieler I; Maurer T; Theisen J; Hatzichristodoulou G; Schwamborn K; Schwaiger M; Eiber M
    J Nucl Med; 2016 Mar; 57(3):367-71. PubMed ID: 26585062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT.
    Chakraborty PS; Tripathi M; Agarwal KK; Kumar R; Vijay MK; Bal C
    Clin Nucl Med; 2015 Feb; 40(2):e163-6. PubMed ID: 25275415
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Rischpler C; Beck TI; Okamoto S; Schlitter AM; Knorr K; Schwaiger M; Gschwend J; Maurer T; Meyer PT; Eiber M
    J Nucl Med; 2018 Sep; 59(9):1406-1411. PubMed ID: 29371407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
    Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [
    Berliner C; Tienken M; Frenzel T; Kobayashi Y; Helberg A; Kirchner U; Klutmann S; Beyersdorff D; Budäus L; Wester HJ; Mester J; Bannas P
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):670-677. PubMed ID: 27896369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.
    Giesel FL; Fiedler H; Stefanova M; Sterzing F; Rius M; Kopka K; Moltz JH; Afshar-Oromieh A; Choyke PL; Haberkorn U; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1794-800. PubMed ID: 26162799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.